Specialty therapies have fundamentally reshaped the pharma commercial model. Just decades ago, fewer than 30 specialty medicines existed. Today, they account for 94% of novel drug approvals. 

That shift isn’t slowing down. 

With over 7,000 therapies in development—and 75% of them classified as specialty drugs—pharmaceutical companies must modernize their commercial strategies to keep pace with this evolving landscape.

What’s driving this transformation? A convergence of regulatory incentives targeting unmet needs, breakthrough innovations in drug development, the rise of digital solutions, and an increasingly empowered patient population. These forces have moved the industry from an HCP-centric model to one that must be relentlessly patient-focused.

In this environment, Field Access and Patient Services teams are no longer support functions—they are strategic partners. These teams coordinate education, access, and adherence support across the care continuum, helping pharma companies bridge the gap between complex therapies and the patients who need them.

Why an HCP-Driven Model Alone Falls Short 

The traditional commercial model relied on sales teams and pharma reps to own the customer relationship. Legacy commercialization strategies focused on HCP relationships and broad customer engagement rather than delivering coordinated, personalized patient support.

This HCP-focused engagement model worked when most therapies were small-molecule, low-complexity treatments that followed simpler, more linear care paths. 

But that model breaks down in today’s specialty drug environment, where:

• Patient journeys are longer and nonlinear.
• Payer requirements are more complex, with rigorous prior authorizations (PAs) and evolving pharma reimbursement standards.
• Patients want personalized engagement and proactive support.
• To ensure continuity of care, real-time coordination among pharmaceutical manufacturers, providers, HUBs, SPs, payers, and others is essential.

Traditional approaches cannot meet these demands. They aren’t equipped to manage PA workflows, more strategically and efficiently engage healthcare providers, ensure patient onboarding, or resolve access barriers. Yet, these are precisely the challenges defining specialty launch success.

For example, more rigorous and frequent PA requirements—occurring across healthcare, according to 80% of surveyed physicians, but more common for specialty therapies—result in more appointments, deadlines, and follow-ups that could affect patient and market access burdens.

Without cross-functional alignment, gaps emerge—missed deadlines, delayed starts, and avoidable therapy abandonment. And the business cost is real: Roughly 30% of patients never initiate therapy, and 66% abandon it within one year. 

These trends present a major challenge for market access in pharma, where payer barriers and care delays directly impact patient access and adherence.

Patient-Centricity as the New Standard 

To compete in today’s commercial environment, biopharma companies must shift from traditional operating models focused on how to drive sales to new commercial models built around patient care and data-driven coordination.

Four core tenets provide the foundation for modern launch solutions for life sciences:

1. Patient-centered focus: Patient journeys—from diagnosis to adherence—must guide all commercial activities. Elevating Field Access and Patient Services in strategic planning ensures every engagement supports timely access, better health outcomes, and a more personalized experience.
2. Connected systems and teams: Modern biopharma companies need full integration—across internal functions (Sales, Market Access, Analytics, Patient Services) and external partners (HCPs, SPs, payers). True coordination requires real-time data sharing and collaborative workflows. When these systems remain siloed, patients fall through the cracks.
3. Data visibility and measurement: Predictive analytics and real-time dashboards enable pharma companies to anticipate risk, identify drop-off points, and create personalization at scale. The mantra is clear: You can’t manage what you can’t measure.
4. Agility and adaptability: The commercial model must adapt to local markets, evolving patient needs, and regulatory shifts. That means developing and updating Standard Operating Procedures (SOPs) to incorporate real-world team and program performance—not just assumptions.

How Technology Enables Integration and Coordination 

Most pharmaceutical companies still rely on legacy tools or cross-industry CRMs that can’t support the high-touch, high-complexity nature of specialty medications. These platforms are often retrofitted through expensive customizations, adding cost and complexity and slowing down operations.

A purpose-built patient CRM like Courier Health equips Field Access and Patient Services with the visibility, automation, and actionable data insights needed to close care gaps.

Unlike legacy systems, it provides:

• Real-time patient journey visibility
• Integration of patient-level and customer data 
• Configurability per therapy 
• Intelligent, omnichannel automation to improve operational efficiency and effectiveness 
• Proactive insights and intelligent next best actions to help move patients and providers towards the next milestone 

Courier Health is more than a CRM—it’s a system of engagement designed to power the patient experience, streamline commercial activities, and improve patient outcomes. 

Why the Time for Transformation Is Now 

Biopharma’s competitive landscape is accelerating, especially as more first-time launchers enter the market with patient-centric strategies from day one. The gap between life sciences industry leaders and laggards is growing. 

Competitive advantage in this new era comes from prioritizing the patient experience, breaking down silos, leveraging data, and enabling personalized engagement through purpose-built technology.

Now is the time to reassess whether your commercial infrastructure is built for the evolving landscape of specialty therapies.

Contact Courier Health to learn how leading biopharma companies operationalize patient-centricity through connected systems and measurable impact.

‍